atezolizumab + bacille calmette-guérin

This is a **combination therapy** of atezolizumab, an intravenous monoclonal antibody targeting programmed death-ligand 1 (PD-L1), and bacille Calmette-Guérin (BCG), an intravesical live attenuated vaccine strain of Mycobacterium bovis, used as immunotherapy for non-muscle invasive bladder cancer (NMIBC). **Atezolizumab** blocks the PD-L1/PD-1 pathway, enhancing T-cell mediated anti-tumor immunity, while **BCG** stimulates a local immune response in the bladder, helping to destroy cancer cells. The combination aims to provide synergistic antitumor effects for high-risk NMIBC, improving disease-free survival and reducing recurrence in patients who are BCG-naïve or BCG-unresponsive. Multiple phase Ib/II trials support safety and preliminary efficacy, with phase 3 research ongoing[1][3][4][6].

Brand names

TecentriqOncoTiceBCG Medac

Other names

atezolizumab + BCGatezolizumab + bacillus Calmette-Guérin